HC Wainwright reaffirmed their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research note issued to investors on Monday. They currently have a $31.00 price objective on the stock.

“Valuation and impediments to achieving price target. We reiterate our Buy rating and $31 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”,” the firm’s analyst commented.

Several other equities research analysts have also commented on KURA. BidaskClub raised shares of Kura Oncology from a sell rating to a hold rating in a research report on Tuesday, November 20th. Oppenheimer set a $32.00 price target on shares of Kura Oncology and gave the company a buy rating in a research report on Wednesday, November 28th. Zacks Investment Research lowered shares of Kura Oncology from a buy rating to a hold rating in a research report on Friday, November 9th. Piper Jaffray Companies began coverage on shares of Kura Oncology in a research report on Friday, November 9th. They set an overweight rating and a $25.00 price target for the company. Finally, ValuEngine lowered shares of Kura Oncology from a strong-buy rating to a buy rating in a research report on Friday, October 19th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $26.86.

Shares of NASDAQ:KURA opened at $13.60 on Monday. Kura Oncology has a fifty-two week low of $10.20 and a fifty-two week high of $24.02. The company has a quick ratio of 14.76, a current ratio of 14.76 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $497.52 million, a price-to-earnings ratio of -8.95 and a beta of 4.41.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Monday, November 5th. The company reported ($0.40) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.01. Sell-side analysts forecast that Kura Oncology will post -1.72 earnings per share for the current year.

In other Kura Oncology news, major shareholder Ecor1 Capital Fund Qualified, purchased 119,906 shares of Kura Oncology stock in a transaction dated Thursday, December 6th. The stock was purchased at an average price of $13.50 per share, with a total value of $1,618,731.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 15.30% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in the stock. Millennium Management LLC grew its stake in shares of Kura Oncology by 0.5% during the 2nd quarter. Millennium Management LLC now owns 524,872 shares of the company’s stock valued at $9,553,000 after acquiring an additional 2,661 shares during the period. Credit Suisse AG grew its stake in shares of Kura Oncology by 36.7% during the 3rd quarter. Credit Suisse AG now owns 18,142 shares of the company’s stock valued at $318,000 after acquiring an additional 4,869 shares during the period. Rhumbline Advisers grew its stake in shares of Kura Oncology by 30.7% during the 2nd quarter. Rhumbline Advisers now owns 23,647 shares of the company’s stock valued at $430,000 after acquiring an additional 5,552 shares during the period. Alliancebernstein L.P. grew its stake in shares of Kura Oncology by 35.1% during the 3rd quarter. Alliancebernstein L.P. now owns 22,700 shares of the company’s stock valued at $397,000 after acquiring an additional 5,900 shares during the period. Finally, Alps Advisors Inc. grew its stake in shares of Kura Oncology by 19.4% during the 2nd quarter. Alps Advisors Inc. now owns 48,400 shares of the company’s stock valued at $881,000 after acquiring an additional 7,874 shares during the period. Institutional investors own 79.28% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Further Reading: How is the LIBOR rate calculated?

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.